Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Chugai Aims to Be No. 1 in Oncology, Nephrology, Bone/Joint Diseases: Mr Nagayama
February 21, 2011
- FDA Adds Actos to List of Drugs with Potential Signals of Serious Risk
February 21, 2011
- DSP to Enhance R&D in Oncology
February 21, 2011
- Sales of Ethical Drugs Down 0.8% in December 2010
February 21, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
- Price Settlement Rate Down to Levels before Emergency Call
February 21, 2011
- Takeda Begins PIII Trial of Alogliptin in China
February 21, 2011
- New Drugs Improve Range of Options for Osteoporosis: 1
February 21, 2011
- Korosho to Carry Out Case Studies to Promote Use of Generics
February 21, 2011
- No Approach from Sawai Since December: Kyorin
February 14, 2011
- MTPC Found to Have Omitted Voluntary Stability Studies as Well
February 14, 2011
- Pharmarise Dispenses Increasing Number of Generics
February 14, 2011
- Quick Answer Required on Efficacy of Dasen
February 14, 2011
- Mr Urushibata to Resign as JPhA Councilor
February 14, 2011
- Initial Sales of Kissei's EPO Biosimilar Disappointing
February 14, 2011
- AZ to Apply for 4 NMEs by 2016 in Japan
February 14, 2011
- JPhA Calls on Members to Settle Prices by End of March
February 14, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…